Krsnaa Diagnostics Q3 FY26 Results: Profit Before Tax ₹212 Cr Standalone, ₹197 Cr Consolidated
Krsnaa Diagnostics reported unaudited standalone results for Q3 FY26 with revenue from operations at ₹1,594.32 crore and profit before tax at ₹212.22 crore. Consolidated revenue from operations was ₹1,812.01 crore with profit before tax at ₹197.66 crore. The company is addressing a tax demand of ₹513.86 million.
The financial results, while containing some negative year-on-year comparisons, are largely in line with expectations. The ongoing tax litigation, although management believes it will not have a material impact, introduces a degree of uncertainty that warrants a medium impact assessment.
The financial results presented are mixed, with some year-on-year declines in profit metrics. While the company is actively managing tax-related issues, the outcome remains uncertain and could potentially impact future financials, leading to a neutral sentiment.
Krsnaa Diagnostics Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 05, 2026.
For the standalone entity, revenue from operations for the quarter was ₹1,594.32 crore, with a profit before tax of ₹212.22 crore. For the nine-month period, revenue from operations stood at ₹5,179.29 crore, and profit before tax was ₹781.89 crore.
On a consolidated basis, revenue from operations for the quarter was ₹1,812.01 crore, and profit before tax was ₹197.66 crore. For the nine-month period, consolidated revenue from operations was ₹5,801.70 crore, with a profit before tax of ₹787.30 crore.
The company also provided an update on tax matters. Following search and seizure proceedings, the Income Tax authorities raised a demand of ₹513.86 million. The company has filed appeals and paid ₹39.27 million under protest, with requests to adjust tax refunds for AY 2024-25. Management believes these matters will not have a material impact on the financial statements.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.